MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Price, Quote, News and Overview
NASDAQ:MREO - Nasdaq - US5894921072 - ADR - Currency: USD
MREO Quote, Performance and Key Statistics
2.85
-0.02 (-0.7%)
The current stock price of MREO is 2.85 USD. In the past month the price decreased by -8.06%. In the past year, price decreased by -22.55%.
MREO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MREO
Company Profile
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Company Info
MEREO BIOPHARMA GROUP PL-ADR
One Cavendish Place, Fourth Floor
London W1G0QF GB
CEO: Denise Scots-Knight
Employees: 33
Company Website: https://www.mereobiopharma.com/
Investor Relations: http://www.mereobiopharma.com/investors/
Phone: 443330237300
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What is the stock price of MEREO BIOPHARMA GROUP PL-ADR today?
The current stock price of MREO is 2.85 USD. The price decreased by -0.7% in the last trading session.
What is the ticker symbol for MEREO BIOPHARMA GROUP PL-ADR stock?
The exchange symbol of MEREO BIOPHARMA GROUP PL-ADR is MREO and it is listed on the Nasdaq exchange.
On which exchange is MREO stock listed?
MREO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MEREO BIOPHARMA GROUP PL-ADR stock?
14 analysts have analysed MREO and the average price target is 7.53 USD. This implies a price increase of 164.33% is expected in the next year compared to the current price of 2.85. Check the MEREO BIOPHARMA GROUP PL-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEREO BIOPHARMA GROUP PL-ADR worth?
MEREO BIOPHARMA GROUP PL-ADR (MREO) has a market capitalization of 442.16M USD. This makes MREO a Small Cap stock.
How many employees does MEREO BIOPHARMA GROUP PL-ADR have?
MEREO BIOPHARMA GROUP PL-ADR (MREO) currently has 33 employees.
What are the support and resistance levels for MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
MEREO BIOPHARMA GROUP PL-ADR (MREO) has a support level at 2.84 and a resistance level at 2.91. Check the full technical report for a detailed analysis of MREO support and resistance levels.
Is MEREO BIOPHARMA GROUP PL-ADR (MREO) expected to grow?
The Revenue of MEREO BIOPHARMA GROUP PL-ADR (MREO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the MREO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MREO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MREO, evaluating the profitability, health, valuation and growth aspects
- MEREO BIOPHARMA GROUP PL-ADR (MREO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEREO BIOPHARMA GROUP PL-ADR (MREO) Sales and EPS estimates to see what analysts future expectations are.
- MEREO BIOPHARMA GROUP PL-ADR (MREO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEREO BIOPHARMA GROUP PL-ADR (MREO) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Chart to make your own analysis
- MEREO BIOPHARMA GROUP PL-ADR (MREO) Latest news and press-releases to stay up to date.
Does MEREO BIOPHARMA GROUP PL-ADR (MREO) stock pay dividends?
MREO does not pay a dividend.
What is the Price/Earnings (PE) ratio of MEREO BIOPHARMA GROUP PL-ADR (MREO)?
MEREO BIOPHARMA GROUP PL-ADR (MREO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.47).
What is the Short Interest ratio of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
The outstanding short interest for MEREO BIOPHARMA GROUP PL-ADR (MREO) is 23.06% of its float. Check the ownership tab for more information on the MREO short interest.
MREO Technical Analysis
MREO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MREO. MREO has a great financial health rating, but its profitability evaluates not so good.
MREO Financial Highlights
Over the last trailing twelve months MREO reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS increased by 25.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74% | ||
| ROE | -90.54% | ||
| Debt/Equity | 0 |
MREO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 89% to MREO. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -11.87% and a revenue growth -100% for MREO